## WHO MDT Regimen for Borderline Lepromatous (BL) Leprosy ### Standard 12-Month Regimen Composition **Key Point:** BL leprosy MDT is a **three-drug regimen**, NOT a four-drug regimen. The drugs are rifampicin, dapsone, and clofazimine only. | Drug | Dose | Frequency | Supervision | | --- | --- | --- | --- | | Rifampicin | 600 mg | Monthly | Supervised | | Dapsone | 100 mg | Daily | Self-administered | | Clofazimine | 50 mg daily + 300 mg monthly | Daily + monthly | Daily self, monthly supervised | ### Why Ofloxacin is NOT Part of Standard BL MDT **High-Yield:** Ofloxacin is **NOT** a standard component of WHO MDT for BL leprosy. It is: - Reserved for **drug-resistant leprosy** (MDT-resistant cases) - Used in **combination regimens** for resistant TB-leprosy co-infection - NOT part of the first-line three-drug regimen for BL **Warning:** Do not confuse BL MDT with regimens for drug-resistant leprosy. The standard BL regimen remains a three-drug combination. ### Duration and Compliance - **12 months** total treatment - Minimum **12 supervised monthly doses** - Daily self-administered doses at home - Cure defined as completion of full regimen ### Mnemonic for BL MDT **"RCD-BL"** = **R**ifampicin, **C**lofazimine (50 mg daily), **D**apsone for **B**orderline **L**epromatous **Clinical Pearl:** The main difference between LL and BL MDT is the **clofazimine dose**—LL receives 100 mg daily, while BL receives 50 mg daily. Both receive the same monthly supervised doses.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.